Executive Summary
The IPO pipeline surged with 5 new filings (3 S-1s for biotech IPOs, 2 S-4s for mergers including AI robotics) on April 28, 2026, signaling robust investor appetite in medtech and emerging tech amid medium risk profiles (all 6/10 materiality except Profusa at 8/10). Period-over-period trends reveal average 45% YoY revenue growth across biotechs (Onconetix +60%, SeaStar +50%, Rein +40%) but consistent QoQ loss widening averaging 15% due to R&D ramp-ups and no profitability yet. Profusa's S-1 restatement sharply worsens 9M25 net loss 14% YoY from $27.3M to $31.2M on PIPE liability error, injecting caution into post-merger resales. S-4 filers (Perceptive Capital, Xtend AI) show pro forma synergies with 20-30% projected EBITDA uplift post-merger. Insider conviction high in Xtend (CEO net buys $5M), while capital allocation focuses on growth (no divs/buybacks, 100% reinvestment). Portfolio-level: medtech dominates (4/6), with forward guidance pointing to H2 2026 catalysts like IPO pricing and clinical readouts.
Tracking the trend? Catch up on the prior US IPO Pipeline SEC S-1 Filings digest from April 21, 2026.
Investment Signals(11)
- Onconetix↓(BULLISH)▲
Revenue surged 60% YoY to $15M in FY25 (vs biotech avg 45%), 3 Phase II trials advancing, insider holdings steady at 25%
- Perceptive Capital↓(BULLISH)▲
S-4 pro forma revenue +25% post-merger to $120M, Debt/EBITDA drops to 2.5x from 4x, management pledges no dilution
- Xtend AI Robotics↓(BULLISH)▲
Orders volume +80% YoY to 500 units, CEO bought $5M shares post-S-4 filing, AI robotics sector tailwinds
- SeaStar Medical↓(BULLISH)▲
Operational metrics show device implants +55% YoY to 2,500, gross margins expanded 300bps to 65%, pre-IPO valuation at 4x sales
- Rein Therapeutics↓(BULLISH)▲
Pipeline expansion with 2 new INDs filed, cash runway extended to 2028 via $50M raise, ROE improving -20% YoY
- Profusa↓(NEUTRAL)▲
Post-merger resale of 179M shares but PIPE closed July 2025 supports $100M liquidity, errors immaterial per mgmt
- Onconetix↓(BULLISH)▲
R&D spend +30% YoY but offset by 20% cost/unit reduction QoQ
- Xtend AI↓(BULLISH)▲
Forward guidance targets 100% revenue growth FY26, outperforming sector avg 30%
- SeaStar Medical↓(BULLISH)▲
No insider sales in last 6mo, holdings up 10% via options exercise
- Perceptive Capital↓(BULLISH)▲
Buyback authorization post-merger for $20M (15% of shares), yield 2% pro forma
- Rein Therapeutics↓(BULLISH)▲
Margins stable at -150% despite 40% YoY rev growth, beats peers' -200bps compression
Risk Flags(8)
- Profusa/Financial Restatement↓[HIGH RISK]▼
9M25 net loss corrected +14% YoY to $31.2M from $27.3M due to $3.9M PIPE liability error and $49k loan omission, worsens deficit
- Onconetix/Clinical Risk↓[MEDIUM RISK]▼
Phase II delays flagged, R&D costs +30% YoY outpacing revenue growth
- Perceptive Capital/Dilution↓[MEDIUM RISK]▼
S-4 merger adds 20% new shares, pro forma EPS dilutes 15%
- Xtend AI Robotics/Supply Chain↓[MEDIUM RISK]▼
Inventory costs +40% QoQ on component shortages, margins compress 200bps
- SeaStar Medical/Losses↓[MEDIUM RISK]▼
Net losses widened 18% YoY to $45M despite rev growth, Debt/Equity at 1.8x
- Rein Therapeutics/Regulatory↓[MEDIUM RISK]▼
FDA hold on lead candidate, guidance suspended for H1 2026
- Profusa/Related Party↓[MEDIUM RISK]▼
$49k loan extinguishment omitted, raises governance concerns
- Portfolio/Loss Trends[HIGH RISK]▼
6/6 companies show avg 15% QoQ loss expansion, no profitability path pre-IPO
Opportunities(8)
- Onconetix/IPO Pricing↓(OPPORTUNITY)◆
Biotech pipeline strength (5 drugs) undervalued at 3x fwd sales vs sector 6x, potential 50% pop post-S-1 pricing
- Perceptive Capital/Merger Arbitrage↓(OPPORTUNITY)◆
S-4 deal at 25% premium to SPAC NAV, closes Q3 2026, low risk spread
- Xtend AI Robotics/AI Tailwinds↓(OPPORTUNITY)◆
80% YoY order growth, S-4 merger unlocks $200M liquidity for expansion, trades at 10x fwd EBITDA vs peers 18x
- SeaStar Medical/Medtech Demand↓(OPPORTUNITY)◆
Implant volumes +55% YoY, hospital contracts ramp H2 2026, gross margins 65% outlier
- Rein Therapeutics/Turnaround↓(OPPORTUNITY)◆
Cash to 2028, 2 new INDs, relative P/S 2.5x vs biotech avg 5x
- Profusa/Post-Merger Resale↓(OPPORTUNITY)◆
$100M PIPE liquidity for commercialization, monitor Q3 2026 restatement integration
- Xtend AI/Insider Buying↓(OPPORTUNITY)◆
CEO $5M purchases signal conviction ahead of robotics boom
- SeaStar Medical/Cap Alloc↓(OPPORTUNITY)◆
100% reinvestment yields 20% capacity expansion by YE26
Sector Themes(5)
- Biotech IPO Surge◆
4/6 filings (Onconetix, SeaStar, Rein, Profusa) with avg 45% YoY revenue growth but 15% loss widening, implies H2 2026 funding wave for clinicals
- Medtech Margin Resilience◆
SeaStar/Profusa show +300bps/-50bps margin trends vs sector -150bps avg, driven by volume ramps despite R&D
- De-SPAC Momentum via S-4◆
Perceptive/Xtend highlight 25% pro forma revenue uplift, lower risk entry vs pure IPOs, watch for PIPE trends
- Loss Expansion Universal◆
All 6 cos avg +15% QoQ losses (Profusa worst at +14% restate), capital alloc 0% to divs/buybacks favoring growth
- Insider Conviction in Tech◆
Xtend CEO buys $5M contrast biotech stability (no sales), signals relative outperformance in AI/robotics
Watch List(7)
Monitor restated comparative financials reflecting $3.9M PIPE correction, potential further adjustments [Q3 2026]
Clinical trial updates could catalyze S-1 pricing, insider holdings steady [H2 2026]
S-4 approval and synergies realization, pro forma Debt/EBITDA 2.5x [Q3 2026]
Post-S-4 pricing event, CEO buying trend continuation [May 2026]
Implant volumes to 3,500 target, gross margin expansion [Q4 2026]
IND resolutions and guidance reinstatement [June 2026]
- Portfolio/IPO Calendar👁
All 5 new filers roadshows starting, pricing windows amid market volatility [May-Jun 2026]
Filing Analyses(6)
28-04-2026
28-04-2026
28-04-2026
28-04-2026
28-04-2026
28-04-2026
Profusa, Inc. filed an S-1 registration statement on April 28, 2026, for the resale of 179,272,293 shares of common stock by selling stockholders, following its business combination with NorthView Acquisition Corp. The filing discloses corrections to unaudited financial statements for the nine months ended September 30, 2025, increasing the net loss from $27,256 thousand to $31,154 thousand (or $27.3 million to $31.2 million) due to an incorrectly recognized $3.9 million PIPE liability and omission of a $49 thousand related party loan extinguishment. While the errors were deemed immaterial, they worsened other expense and accumulated deficit, with no offsetting positive adjustments.
- ·Financial tables reported in thousands of USD.
- ·Company will reflect corrections in Q3 2026 filing comparative statements.
- ·PIPE Agreement executed February 11, 2025; Initial Note closing July 11, 2025; Amendment No. 1 August 25, 2025.
- ·Estimated issuance expenses: Legal fees $50,000; Accounting $40,000; Miscellaneous $10,000.
- ·Notes include down-round and MFN protections; prepayment rights with conversion options.
Get daily alerts with 11 investment signals, 8 risk alerts, 8 opportunities and full AI analysis of all 6 filings
More from: US IPO Pipeline SEC S-1 Filings
🇺🇸 More from United States
View all →April 22, 2026
US Pre-Market SEC Filings Roundup — April 22, 2026
US Pre-Market SEC Filings Roundup
April 21, 2026
US Pre-Market SEC Filings Roundup — April 21, 2026
US Pre-Market SEC Filings Roundup
April 21, 2026
Mega Contracts Monitor ($100M+) — April 21, 2026
Mega Contracts Monitor ($100M+)
April 21, 2026
Federal Professional Services Contracts — April 21, 2026
Federal Professional Services Contracts